Phase 3 clinical trials are also ongoing in the first-line setting with these compounds (Table 2), and their results will shed light on the next steps forward in treating patients with EGFR exon 20 insertion-positive NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.